AstraZeneca (NASDAQ:AZN) Upgraded at Deutsche Bank Aktiengesellschaft

AstraZeneca (NASDAQ:AZN) was upgraded by equities research analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report issued on Wednesday, FinViz reports.

Several other analysts have also weighed in on AZN. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 7.2 %

AZN opened at $66.27 on Wednesday. The firm has a market cap of $205.48 billion, a price-to-earnings ratio of 32.01, a PEG ratio of 1.32 and a beta of 0.47. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm’s 50-day simple moving average is $78.87 and its 200-day simple moving average is $78.77. AstraZeneca has a twelve month low of $60.47 and a twelve month high of $87.68.

Institutional Trading of AstraZeneca

Several hedge funds have recently modified their holdings of AZN. McClarren Financial Advisors Inc. boosted its holdings in AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after acquiring an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca during the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter valued at about $28,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, RFP Financial Group LLC grew its position in shares of AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after buying an additional 178 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.